The global allergy diagnostics market size is calculated at USD 5.79 billion in 2024, grew to USD 6.42 billion in 2025, and is projected to reach around USD 16.45 billion by 2034. The market is expanding at a CAGR of 10.96% between 2025 and 2034.
Rising Investments: Investments are raised to develop and deliver advanced diagnostics to patients globally.
Increasing Collaboration: Major companies collaborate to access advanced technologies and develop innovative allergy diagnostics. They also expand their geographical presence, serving a large patient population.
Key players, such as Thermo Fisher Scientific, Danaher Corporation, and Hycor Biomedical, deliver innovative allergy diagnostics in the U.S. The Food and Drug Administration (FDA) regulates the approval of diagnostics and allergen extracts. As of 2024, the U.S. FDA has approved a total of 19 allergen extracts.
Asthma Canada reported that 1 in 5 Canadians suffers from respiratory allergies annually. The Food Allergy Canada’s National Food Allergy Action Plan (NFAAP) helps Canadians with food allergies with its prevention, diagnosis, and treatment. The federal government invested $4.5 million over 2 years for the NFAAP.
Allergic diseases are estimated to affect around 40% of the Chinese population. Healthcare expenditure in China facilitates the use of advanced technologies for allergies. It is estimated that healthcare expenditure will reach RMB 205 trillion by 2030. China is also emerging as a global hub for clinical trials, surpassing the U.S. and Europe.
In India, about 22% of adolescents are estimated to have allergic rhinitis. India’s health spending rose to Rs 6.1 lakh crore in 2024-25, an increase from Rs 3.2 lakh crore in 2020-21, accounting for 3.8% of the GDP. Alcit India Pvt. Ltd., AllVac Pharmaceuticals, and Asian Diagnostics are the major providers of allergy diagnostics in India.
The research activities for allergy diagnostics include the development of point-of-care diagnostics, automated devices leveraged with AI, and novel assay procedures.
Key Players: Danaher Corporation, Neogen Corporation, and Siemens Healthineers
Innovative diagnostics are tested for their safety and efficacy in clinical trials. After conducting clinical trials, regulatory agencies approve a diagnostic based on its trial data.
Key Players: Boehringer Ingelheim, MacroArray Diagnostics GmbH, and Hycor Biomedical
Patient support & services refer to providing information about different diagnostic methodologies and tailored treatments, enabling patients to manage conditions and improve their quality of life.
Javier Evelyn, Founder and CEO of Alerje, commented that the partnership with MGCC represents a significant milestone in their mission to improve the lives of millions affected by allergies. He also stated that the company is poised to deliver unprecedented advancements in allergy diagnosis and management by combining the expertise of both companies.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
